NCT00059618View on ClinicalTrials.gov

PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

April 30, 2007

Study Completion Date

April 30, 2007

Conditions
Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Interventions
DRUG

PS-341 (Bortezomib)

Starting dose 0.8 mg/m\^2 given by vein over 5-10 seconds Day 1, 4, 8 and 11 of 28 day cycle for 8 cycles.

DRUG

Carboplatin

AUC 5 by vein administered over one hour Day 1 of 28 day cycle for 8 cycles.

Trial Locations (1)

77030

University of Texas M. D. Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00059618 - PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer | Biotech Hunter | Biotech Hunter